What We Do

Our main research focus is to improve patient outcomes by gaining deeper understanding of lymphoma biology and disease progression which can be translated into clinical applications. Our ultimate goal is to improve patient outcomes through enhanced precision medicine, which can be designed using advanced genomic tools.

News & Events

Study reveals cause for different outcomes for patients that experience early and late relapse of diffuse large B-cell lymphoma

A recent study conducted by TFRI-funded researchers at BC Cancer sheds light on the cause behind the different outcomes of patients with diffuse large B cell lymphoma (DLBCL) who experienced a relapse in their disease. The study confirmed that patients whose cancer relapses shortly after treatment typically have poor responses to additional chemotherapy-based treatment. However, when the relapse occurs more than two years from the time of diagnosis, the outcomes to chemotherapy are significantly better.

Research reveals insights into lymphoma relapse and treatment response

A recent study conducted by researchers at BC Cancer has shed light on the cause behind the different outcomes of patients with diffuse large B-cell lymphoma (DLBCL) who experience a relapse of their disease. The study, led by Dr. Laura Hilton, staff scientist at BC Cancer’s Centre for Lymphoid Cancer (CLC), and Dr. David Scott, clinical director of the CLC, aimed to understand the molecular characteristics of the initial diagnostic and relapse tumour samples of patients with DLBCL.

BCCF Innovation Support Fund Awardees

The BCCF Innovation Support Fund Awardees are:

  • Ly Vu & Christian Steidl - equipment: Bio-Rad ChemiDoc Imaging System
  • Pamela Hoodless - equipment: Thermo EVOS M5000 Cell Imaging Microscope

The BC Cancer Foundation, in partnership with BC Cancer, established the Innovation Support Fund competition in 2010 to enable the acquisition of equipment essential to conducting research. 

Research Labs & Principal Investigators

Recent Publications

Genomic Profiling for Clinical Decision Making in Lymphoid Neoplasms

Blood, 2022
Laurence de Leval, Ash A Alizadeh, P Leif Bergsagel, Elias Campo, Andrew John Davies, Ahmet Dogan, Jude Fitzgibbon, Steven M. Horwitz, Ari M. Melnick, William George Morice, Ryan D Morin, Bertrand Nadel, Stefano A Pileri, Professor, Richard Rosenquist, Davide Rossi, Itziar Salaverria, Christian Steidl, Steven P Treon, Andrew D. Zelenetz, Ranjana Advani, Carl E Allen, Stephen M. Ansell, Wing C. Chan, James R. Cook, Lucy B Cook, Francesco d'Amore, Stefan Dirnhofer, Martin Dreyling, Kieron Dunleavy, Andrew Feldman, Falko Fend, Philippe GAULARD, Paolo Ghia, John G Gribben, Olivier Hermine, Daniel J Hodson, Eric D. Hsi, Giorgio GA Inghirami, Elaine S. Jaffe, Kennosuke Karube, Keisuke Kataoka, Wolfram Klapper, Won Seog Kim, Rebecca L King, Young Hyeh Ko, Ann S. LaCasce, Georg Lenz, Iñaki Martin-Subero, Miguel A Piris, Stefania Pittaluga, Laura Pasqualucci, Leticia Quintanilla-Martinez, Scott J. Rodig, Andreas Rosenwald, Gilles A. Salles, Jesus San-Miguel, Kerry J. Savage, Laurie H. Sehn, Gianpietro Semenzato, Louis M Staudt, Steven Howard Swerdlow, Constantine S. Tam, Judith Trotman, Julie Vose, Oliver Weigert, Wyndham H. Wilson, Jane N Winter, Catherine J. Wu, Pier Luigi Zinzani, Emanuele Zucca, Adam Bagg, David W. W. Scott
Learn More

Molecular Determinants of Clinical Outcomes In a Real-World Diffuse Large B-cell Lymphoma Population

Blood, 2022
Waleed Alduaij, Brett J Collinge, Susana Ben-Neriah, Aixiang Jiang, Laura K Hilton, Merrill Boyle, Barbara Meissner, Lauren C. Chong, Tomoko Miyata-Takata, Graham W. Slack, Pedro Farinha, Jeffrey W Craig, Andrew Lytle, Kerry J. Savage, Diego Villa, Alina S. Gerrie, Ciara L. Freeman, Randy D. Gascoyne, Joseph M Connors, Ryan D Morin, Laurie H. Sehn, Andrew J Mungall, Christian Steidl, David W. Scott
Learn More
Back to top